Kymera Therapeutics (KYMR) Stock Price, News & Analysis

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KYMR shares.
View KYMR analyst ratings or view top-rated stocks.

12 brokers have issued twelve-month price objectives for Kymera Therapeutics' stock. Their KYMR share price targets range from $24.00 to $56.00. On average, they expect the company's share price to reach $39.89 in the next year. This suggests a possible upside of 18.2% from the stock's current price.
View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts.

Kymera Therapeutics' stock was trading at $25.46 on January 1st, 2024. Since then, KYMR shares have increased by 32.6% and is now trading at $33.76.
View the best growth stocks for 2024 here.

Kymera Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,060,000 shares, an increase of 8.8% from the March 15th total of 8,330,000 shares. Based on an average trading volume of 752,000 shares, the short-interest ratio is presently 12.0 days.
View Kymera Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KYMR earnings forecast.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) released its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.19. The firm earned $47.90 million during the quarter, compared to the consensus estimate of $41.94 million. Kymera Therapeutics had a negative net margin of 187.00% and a negative trailing twelve-month return on equity of 34.83%. Kymera Therapeutics's revenue was up 197.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.60) earnings per share.

ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

Kymera Therapeutics (KYMR) raised $126 million in an initial public offering (IPO) on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Kymera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.08%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Ellen Chiniara, Jared Gollob, Jeffrey W Albers, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends.

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.